Table 2.
Evidence of Osteoporosis Screening or Prevention by Physicians
Variable | Level | White Women (n=102) | African-American Women (n=103) | Odds Ratio (95% Confidence Interval) |
---|---|---|---|---|
DXA referral | Yes | 56 | 33 | – |
No | 46 | 70 | 0.39 (0.22, 0.68) | |
Completed DXA, if referred | Yes | 44 | 24 | – |
No | 12 | 9 | 0.73 (0.27, 1.93) | |
Peripheral bone density measurement referral | Yes | 6 | 2 | – |
No | 96 | 101 | 0.32 (0, 1.41) | |
Documentation of consideration of osteoporosis in physician notes | Yes | 73 | 41 | – |
No | 29 | 61 | 0.27 (0.15, 0.48) | |
Recommendation of calcium and/or vitamin D supplementation | Yes | 71 | 33 | – |
No | 31 | 70 | 0.21 (0.11, 0.37) | |
Recommendation of HT or raloxifene | Yes | 29 | 9 | – |
No | 65 | 90 | 0.22 (0.10, 0.50) | |
Recommendation of calcitonin or bisphosphonates | Yes | 46 | 19 | – |
No | 56 | 84 | 0.28 (0.15, 0.52) |
DXA, dual energy x-ray absorptiometry; HT, hormone therapy.